WO2006086454A3 - Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms - Google Patents

Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms Download PDF

Info

Publication number
WO2006086454A3
WO2006086454A3 PCT/US2006/004397 US2006004397W WO2006086454A3 WO 2006086454 A3 WO2006086454 A3 WO 2006086454A3 US 2006004397 W US2006004397 W US 2006004397W WO 2006086454 A3 WO2006086454 A3 WO 2006086454A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
life span
cells
organisms
increasing
Prior art date
Application number
PCT/US2006/004397
Other languages
French (fr)
Other versions
WO2006086454A2 (en
Inventor
David A Sinclair
Kevin J Bitterman
Original Assignee
Harvard College
David A Sinclair
Kevin J Bitterman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, David A Sinclair, Kevin J Bitterman filed Critical Harvard College
Priority to CA2595495A priority Critical patent/CA2595495C/en
Priority to ES06734562T priority patent/ES2401342T3/en
Priority to AU2006212770A priority patent/AU2006212770B2/en
Priority to EP06734562A priority patent/EP1851240B1/en
Priority to JP2007554337A priority patent/JP2008529502A/en
Publication of WO2006086454A2 publication Critical patent/WO2006086454A2/en
Publication of WO2006086454A3 publication Critical patent/WO2006086454A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Abstract

The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more proteins selected from the group consisting of NPTl, PNCl, NMAl and NMA2. Another method comprises
PCT/US2006/004397 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms WO2006086454A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2595495A CA2595495C (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
ES06734562T ES2401342T3 (en) 2005-02-08 2006-02-08 Methods and compositions to prolong the period of life and increase the resistance to stress of cells and organisms
AU2006212770A AU2006212770B2 (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP06734562A EP1851240B1 (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP2007554337A JP2008529502A (en) 2005-02-08 2006-02-08 Methods and compositions for extending cell and organism life and increasing stress tolerance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/053,185 US7977049B2 (en) 2002-08-09 2005-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US11/053,185 2005-02-08

Publications (2)

Publication Number Publication Date
WO2006086454A2 WO2006086454A2 (en) 2006-08-17
WO2006086454A3 true WO2006086454A3 (en) 2007-03-29

Family

ID=36591266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/004397 WO2006086454A2 (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Country Status (7)

Country Link
US (2) US7977049B2 (en)
EP (1) EP1851240B1 (en)
JP (3) JP2008529502A (en)
AU (1) AU2006212770B2 (en)
CA (1) CA2595495C (en)
ES (1) ES2401342T3 (en)
WO (1) WO2006086454A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421269A1 (en) * 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2548671C (en) 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2006068656A2 (en) * 2004-05-04 2006-06-29 President And Fellows Of Harvard College Methods and compositions for inducing sirtuins
US7776326B2 (en) * 2004-06-04 2010-08-17 Washington University Methods and compositions for treating neuropathies
KR101331677B1 (en) * 2004-09-24 2013-11-26 바이엘 크롭사이언스 엔.브이. Stress resistant plants
WO2006076681A2 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2006105440A2 (en) * 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20090137681A1 (en) * 2005-04-08 2009-05-28 David A Sinclair Sirtuin Inhibiting Compounds
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1757284A1 (en) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP3369738B1 (en) * 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Method for making nicotinoyl ribosides and nicotinamide beta-riboside
WO2007101122A2 (en) * 2006-02-24 2007-09-07 University Of Chicago Methods and compositions involving slc17a1
US8158856B2 (en) * 2006-03-21 2012-04-17 Bayer Cropscience Nv Stress resistant plants
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
EP2124552A4 (en) * 2007-01-31 2013-01-09 Methylation Sciences Internat Srl Extended release pharmaceutical formulations of s-adenosylmethionine
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
WO2008095056A2 (en) * 2007-02-01 2008-08-07 The Wistar Institute Method for identifying a compound that modulates sir2 protein activity
US20110082189A1 (en) * 2007-10-23 2011-04-07 President And Fellows Of Harvard College Use of compounds activating sirt-3 for mimicking exercise
AU2008334090A1 (en) * 2007-11-30 2009-06-11 Daniel V. Santi Industrial production of organic compounds using recombinant organisms expressing methyl halide transferase
JP5570731B2 (en) * 2008-02-28 2014-08-13 旭化成ファーマ株式会社 Method for measuring pyrophosphate
CA2745376A1 (en) * 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN107595841A (en) 2009-01-09 2018-01-19 得克萨斯州大学系统董事会 Preceding neurogenic compounds
CA2805041A1 (en) 2009-07-22 2011-01-27 The Regents Of The University Of California Cell-based systems for production of methyl formate
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
GB201007197D0 (en) * 2010-04-30 2010-06-16 Ge Healthcare Uk Ltd Methods and kits for determining the toxicity of an agent
CA2804161A1 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9072766B2 (en) * 2010-11-18 2015-07-07 Beth Israel Deaconess Medical Center, Inc. Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
EP2726477A4 (en) * 2011-06-29 2015-08-26 Harvard College Small molecule cd38 inhibitors and methods of using same
WO2014059031A2 (en) * 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors in the prevention and treatment of inflammation
US9877981B2 (en) 2012-10-09 2018-01-30 President And Fellows Of Harvard College NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
EP3063163B1 (en) 2013-10-30 2022-08-10 Chromadex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
TWI638047B (en) 2014-04-09 2018-10-11 史基普研究協會 Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
CA2950727A1 (en) 2014-06-02 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Preparation and use of crystalline beta-d-nicotinamide riboside
PL3670522T3 (en) 2014-07-24 2022-02-21 W.R. Grace & Co. - Conn. Crystalline form of nicotinamide riboside chloride
US9995758B1 (en) * 2014-10-31 2018-06-12 Western Autotroph Company LLC Methods and systems for controlling oxidative stress in humans and animals
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
AU2016255853B2 (en) 2015-04-28 2021-08-05 Newsouth Innovations Pty Limited Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
US20160317419A1 (en) * 2015-05-01 2016-11-03 The Procter & Gamble Company Method of improving skin health and compositions therefor
US20160317418A1 (en) 2015-05-01 2016-11-03 The Procter & Gamble Company Method of improving the appearance of skin and compositions therefor
WO2017004101A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
US20160374918A1 (en) 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
BR112018002168B1 (en) 2015-08-05 2023-10-10 Metro International Biotech, Llc COMPOUND, OR A STEREOISOMER OR SALT THEREOF, USE OF THE COMPOUND AND COMPOSITION COMPRISING A COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN108430449B (en) 2016-01-11 2023-01-24 宝洁公司 Methods of treating skin conditions and compositions therefor
CA3020728A1 (en) * 2016-03-31 2017-10-05 Berkeley Lights, Inc. Nucleic acid stabilization reagent, kits, and methods of use thereof
CA3021571C (en) * 2016-04-20 2023-01-03 ChromaDex Inc. Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors
AU2017356475B2 (en) 2016-11-11 2023-11-30 ChromaDex Inc. Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US11633421B2 (en) 2016-11-29 2023-04-25 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
WO2018129039A1 (en) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
CN110785161B (en) 2017-06-23 2023-06-20 宝洁公司 Compositions and methods for improving the appearance of skin
TWI821192B (en) 2017-07-11 2023-11-11 美商新索思股份有限公司 Incorporation of unnatural nucleotides and methods thereof
KR20200035092A (en) 2017-08-03 2020-04-01 신톡스, 인크. Cytokine conjugates for the treatment of autoimmune diseases
CA3086535A1 (en) 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
KR20210011964A (en) 2018-07-03 2021-02-02 더 프록터 앤드 갬블 캄파니 How to treat a skin condition
SG11202107354WA (en) 2019-02-06 2021-08-30 Synthorx Inc Il-2 conjugates and methods of use thereof
US11491175B2 (en) 2019-02-25 2022-11-08 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for enhancing cellular energy
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
WO2021030551A1 (en) * 2019-08-14 2021-02-18 Metro International Biotech, Llc Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide
CN110973260A (en) * 2019-12-11 2020-04-10 杨力 Nicotinamide riboside-containing milk and preparation method and application thereof
CN111394268B (en) * 2019-12-20 2021-06-18 合肥康诺生物制药有限公司 Genetically engineered bacterium, construction method and application thereof, and NAD (nicotinamide adenine dinucleotide) production+Method (2)
JP2023528616A (en) 2020-06-01 2023-07-05 ザ プロクター アンド ギャンブル カンパニー Method for improving skin penetration of vitamin B3 compounds
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
US20230265516A1 (en) * 2020-08-07 2023-08-24 University Of Arizona, Arizona Board Of Regents Single nucleotide polymorphisms and treatment of inflammatory conditions
EP4346842A1 (en) 2021-05-27 2024-04-10 Metro International Biotech, LLC Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
WO2023086770A1 (en) * 2021-11-10 2023-05-19 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection gene therapy
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016726A2 (en) * 2002-08-09 2004-02-26 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179937A (en) 1978-06-02 1979-12-25 Ocean Ecology Ltd. Sound measuring device
FR2543550B1 (en) * 1983-04-01 1985-08-09 Cortial NOVEL TETRAHYDROXY-3 ', 4', 5.7 FLAVONE DERIVATIVES, THEIR PREPARATION METHOD AND THEIR THERAPEUTIC USE
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS63152309A (en) * 1986-08-11 1988-06-24 Lion Corp External preparation of skin
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DE3733017A1 (en) 1987-09-30 1989-04-13 Bayer Ag Stilbene synthase gene
US5689046A (en) * 1987-09-30 1997-11-18 Bayer Aktiengesellschaft Stilbene synthase gene
CA1336169C (en) * 1988-03-01 1995-07-04 Walther Birkmayer Agent for treatment of parkinson's disease
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE4107396A1 (en) * 1990-06-29 1992-01-02 Bayer Ag STYLE SYNTHASE GENES FROM VINEYARD
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
JP3214049B2 (en) 1992-03-09 2001-10-02 史衛 佐藤 Method for producing cis-olefin
DE4232899C2 (en) * 1992-09-30 1995-02-23 Birkmayer Joerg Univ Prof Dr Use of NADH and NADPH to treat Alzheimer's disease
IL107642A0 (en) * 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
PL179877B1 (en) 1993-07-13 2000-11-30 Rhone Poulenc Rorer Sa Viral vectors and their application in genic therapy
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US6048903A (en) * 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
ATE336587T1 (en) 1994-06-10 2006-09-15 Genvec Inc ADENOVIRUS VECTOR SYSTEMS AND CELL LINES
DK0787200T3 (en) 1994-10-28 2005-08-15 Univ Pennsylvania Improved adenovirus and methods for its use
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
DE4440200A1 (en) * 1994-11-10 1996-05-15 Bayer Ag DNA sequences and their use
NZ300387A (en) 1994-12-12 2001-07-27 Genetic Therapy Inc Adenoviral vector modified to reduce host immune and inflammatory responses and its use in gene therapy treatment
DE4444238A1 (en) * 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
AU697022B2 (en) 1995-02-24 1998-09-24 Trustees Of The University Of Pennsylvania, The Methods and compositions for administering gene therapy vectors
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
EP0847442A1 (en) 1995-08-30 1998-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
IT1276225B1 (en) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ALKANOYL L-CARNITINE IN ASSOCIATION WITH RESVERATROL OR ITS DERIVATIVES USEFUL FOR
FR2741238B1 (en) * 1995-11-17 2001-11-30 Goemar Lab Sa USE OF ALUMINUM CHLORIDE AS AN ELICITOR OF RESVERATROL SYNTHESIS
US6124125A (en) * 1996-01-08 2000-09-26 Trustees Of Dartmouth College AMP activated protein kinase
DE19624668A1 (en) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Use of pyridylalkane, pyridylalken or pyridylalkynamides
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
IT1291113B1 (en) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti NUTRITIONAL THERAPEUTIC COMPOSITION FOR SUBJECTS WITH DIABETES MELLITUS
FR2766176B1 (en) * 1997-07-15 1999-10-29 Caudalie COMPOSITIONS BASED ON RESVERATROL DERIVATIVES
US6270780B1 (en) * 1997-07-25 2001-08-07 Chesebrough-Pond's Usa Co., Division Of Conopco Cosmetic compositions containing resveratrol
BR9803596A (en) * 1997-09-23 2000-04-25 Pfizer Prod Inc Derivatives of resorcinol.
EP1032403B1 (en) * 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US6008260A (en) 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
AT407821B (en) * 1998-03-24 2001-06-25 Franz Dr Stueckler MEDIUM BASED ON NATURAL SUBSTANCES
US6245814B1 (en) * 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6624197B1 (en) * 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6448450B1 (en) * 1998-05-08 2002-09-10 Calyx Therapeutics, Inc. 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment
US6022901A (en) * 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
ATE324105T1 (en) 1998-09-08 2006-05-15 Cornell Res Foundation Inc USE OF CYCLOOXYGENASE-2 INHIBITORS TO TREAT INFLAMMATORY DISEASES OF THE HEAD AND NECK
US6656925B2 (en) * 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
IT1302365B1 (en) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa USE OF CARNITINE AND RESVERATROL TO PRODUCE A COMPOSITION FOR THE PREVENTION OR THERAPEUTIC TREATMENT OF BRAIN ALTERATIONS
US20030078212A1 (en) 1998-10-30 2003-04-24 Jia-He Li Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
US6361815B1 (en) * 1998-12-21 2002-03-26 Pure World Botanicals, Inc. Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use
US6190716B1 (en) * 1999-02-17 2001-02-20 Scott O. Galbreath, Jr. Method for preparing a grape derived product
FR2790645B1 (en) 1999-03-12 2001-06-08 Arkopharma Laboratoires FOOD SUPPLEMENT AND COSMETIC TREATMENT METHOD BASED ON GRAPE EXTRACT RICH IN POLYPHENOLS
US6878381B2 (en) 1999-03-22 2005-04-12 Pfizer, Inc Resorcinol composition
US6844163B1 (en) * 1999-04-12 2005-01-18 Sumitomo Chemical Co., Ltd. Method for analyzing the amount of intraabdominal adipose tissue
FR2795643B1 (en) 1999-07-02 2004-06-11 Oreal FIRMING COSMETIC COMPOSITION INCLUDING AT LEAST ONE HYDROXYSTILBENE IN ASSOCIATION WITH ASCORBIC ACID
ATE281179T1 (en) 1999-08-13 2004-11-15 Univ Maryland Biotech Inst COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS THEREOF
JP2003508488A (en) * 1999-09-03 2003-03-04 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ Ultrafine L-carnitine, method for its preparation, composition containing it, and method for its use
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
AU7596100A (en) * 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6264995B1 (en) * 1999-10-19 2001-07-24 Thomas Newmark Herbal composition for reducing inflammation and methods of using same
US6358517B1 (en) * 1999-10-22 2002-03-19 Unilever Home & Personal Care Usa, Division Of Conopco Cosmetic compositions containing resveratrol and retinoids
US20020002200A1 (en) 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US6416806B1 (en) * 2000-03-20 2002-07-09 James H. Zhou Herbal caffeine replacement composition and food products incorporating same
US20010039296A1 (en) 2000-03-23 2001-11-08 Debasis Bagchi Method and composition for preventing or reducing the symptoms of menopause
IT1318425B1 (en) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro USE OF RESVERATROL FOR THE TREATMENT OF DESQUAMATIVE ECZEMA, ACNE AND PSORIASIS.
IT1317034B1 (en) 2000-05-30 2003-05-26 Istituto Di Medicina Speriment METHOD OF EXTRACTION OF PHARMACEUTICAL ACTIVITY PRODUCTS FROM PLANTS SPERMATOPHYTES, PRODUCTS SO OBTAINED AND THEIR USE IN MEDICINE, IN
US6475530B1 (en) 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
ITNA20000037A1 (en) 2000-06-02 2001-12-02 Dev Biotechnological Proces Se INNOVATIVE MULTIFUNCTION SOLAR FILTER.
ITNA20000036A1 (en) 2000-06-02 2001-12-02 Dev Biotechnological Proces Se NEW THERAPEUTIC APPROACHES FOR THE TREATMENT OF DANDRUFF.
IT1318565B1 (en) 2000-06-09 2003-08-27 World Pharma Tech Ltd NADH OCTOCOSANOL EVITAMIN E PROENERGETIC FOOD SUPPLEMENT
US6795856B1 (en) 2000-06-28 2004-09-21 Accountability International, Inc. System and method for monitoring the internet access of a computer
US6319523B1 (en) 2000-06-29 2001-11-20 James H. Zhou Composition and method for inhibiting oral bacteria
US20020120008A1 (en) * 2000-06-29 2002-08-29 Seymour Benzer Life extension of drosophila by a drug treatment
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
DE10034320A1 (en) * 2000-07-14 2002-02-07 Inst Pflanzenbiochemie Ipb Process for influencing the sinapine content in transgenic plant cells and plants
FR2812195B1 (en) * 2000-07-28 2003-07-11 Oreal TOPICAL APPLICATION COMPOSITIONS COMPRISING GLUCOSYLATED HYDROXYSTILBENES AND UTILIZATIONS
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
US6541522B2 (en) * 2000-08-16 2003-04-01 Insmed Incorporated Methods of using compositions containing hypotriglyceridemically active stilbenoids
US6410596B1 (en) * 2000-08-16 2002-06-25 Insmed Incorporated Compositions containing hypoglycemically active stillbenoids
US6552085B2 (en) * 2000-08-16 2003-04-22 Insmed Incorporated Compositions containing hypoglycemically active stilbenoids
US20020173549A1 (en) 2000-11-08 2002-11-21 Wurtman Richard J. Compositions and methods for treatment of mild cognitive impairment
CA2431196C (en) * 2000-11-15 2012-01-24 Rutgers, The State University Of New Jersey Black tea extract for prevention of disease
US20030165854A1 (en) * 2000-12-05 2003-09-04 Cunningham Mary Jane Marker genes responding to treatment with toxins
US20030082647A1 (en) * 2000-12-12 2003-05-01 Reenan Robert A. Transporter protein
US20040005574A1 (en) * 2002-07-08 2004-01-08 Leonard Guarente SIR2 activity
AU2002226650A1 (en) 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
WO2004096256A1 (en) 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
FR2820320B1 (en) * 2001-02-02 2003-04-04 Oreal SUSPENSION OF LIPOPHILIC ACTIVE INGREDIENT NANOSPHERES STABILIZED BY WATER-DISPERSIBLE POLYMERS
US20020192310A1 (en) 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
US20030190381A1 (en) 2001-02-02 2003-10-09 Bland Jeffrey S. Medical composition for balancing bodily processes
CA2439109A1 (en) * 2001-02-20 2002-10-17 Uab Research Foundation Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
US6300377B1 (en) * 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
ITPI20010014A1 (en) * 2001-03-05 2002-09-05 Ivo Pera COMPOUND FOR FILTERS FOR CIGARETTES, OR OTHER SMOKING ITEMS, BASED ON ANTIOXIDANT SUBSTANCES AND THE FILTER SO OBTAINED
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
US20030044946A1 (en) * 2001-04-03 2003-03-06 Longo Valter D. Genes, mutations, and drugs that increase cellular resistance to damage and extend longevity in organisms from yeast to humans
US6387416B1 (en) * 2001-04-05 2002-05-14 Thomas Newmark Anti-Inflammatory herbal composition and method of use
US20030180719A1 (en) * 2001-04-13 2003-09-25 Thomas Herget Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections
WO2002085327A2 (en) * 2001-04-18 2002-10-31 Oraltech Pharmaceuticals, Inc. Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6426061B1 (en) * 2001-04-20 2002-07-30 Weiwei Li Method and composition for preventing sweat-related odor
DE60236273D1 (en) 2001-05-03 2010-06-17 Cornell Res Foundation Inc TREATMENT OF DISEASES CAUSED BY HPV
US6368617B1 (en) * 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
AU2002318364A1 (en) * 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
AU2002315166A1 (en) * 2001-06-15 2003-01-02 The Trustees Of Columbia University In The City Of New York Sir2alpha-based therapeutic and prophylactic methods
CN1398838A (en) 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 Diphenylethylene compound and its prepn and application in preventing and treating diabetes
US20030044474A1 (en) * 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
US7396546B2 (en) 2001-08-06 2008-07-08 The Quigley Corporation Anti-microbial compositions and methods of using same
CA2457370A1 (en) * 2001-08-15 2003-02-27 Elixir Pharmaceuticals, Inc. Age-associated markers
US6841578B2 (en) * 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
US20030055114A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
US6656969B2 (en) * 2001-09-20 2003-12-02 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
US20030054053A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
US6680342B2 (en) * 2001-09-20 2004-01-20 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
PL369336A1 (en) * 2001-09-21 2005-04-18 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
US20030082116A1 (en) * 2001-09-28 2003-05-01 Closure Medical Corporation Adhesive compositions containing dual function stabilizers and active agents
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
EP1304161B1 (en) * 2001-10-19 2007-02-28 Pacific Corporation Thermotropic liquid crystal polymer microcapsules, a method for preparing the same, and cosmetic compositions containing the same
EP1304048B1 (en) * 2001-10-22 2004-09-22 Ivo Pera Composition to reduce or quit smoking addiction
US6767563B2 (en) * 2001-10-30 2004-07-27 Michael D. Farley Immune functions
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
CN1310937C (en) * 2001-11-21 2007-04-18 犹太大学阿尔伯特爱因斯坦医学院 Sir2 products and activities
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition
FR2832630B1 (en) * 2001-11-28 2005-01-14 Oreal COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE OXIDATION-SENSITIVE HYDROPHILIC ACTIVE STABILIZED WITH AT LEAST ONE COPOLYMER OF N-VINYLIMIDAZOLE
US20030118617A1 (en) * 2001-12-21 2003-06-26 Avon Products, Inc. Resveratrol analogues
NZ516366A (en) * 2001-12-24 2004-07-30 Enzo Nutraceuticals Ltd Increased lifespan formulation using pine bark flavonoid extract
AU2002367363A1 (en) * 2001-12-26 2003-07-24 The Regents Of The University Of California System and method for identifying networks of ternary relationships in complex data systems
AU2003210477A1 (en) * 2002-01-09 2003-07-30 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
DK1487431T3 (en) 2002-03-08 2012-08-20 Philera New Zealand Ltd Prevention and / or treatment of cardiovascular disease and / or associated heart failure
AU2003220240A1 (en) 2002-03-13 2003-09-29 Biophysica, Inc. Boswellin compositions enhanced with 3-beta-acety1-11-keto-beta-boswellic acid (akba), industrial manufacture and their uses
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
DE60202603T2 (en) 2002-03-28 2005-12-29 Council Of Scientific And Industrial Research 8- (C-BETA-D-GLUCOPYRANOSYL) -7,3 ', 4'-TRIHYDROXYFLAVONE, METHOD FOR THE ISOLATION OF PTEROCARPUS MARSUPIUM AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
US20030224077A1 (en) 2002-04-08 2003-12-04 Societe L'oreal S.A. Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase
AU2003221767B2 (en) * 2002-04-24 2008-07-31 Research Development Foundation Synergistic effects of nuclear transcription factor NF-kB inhibitors and anti-neoplastic agents
WO2003094833A2 (en) * 2002-05-10 2003-11-20 Orchid Chemicals & Pharmaceuticals Limited A new stereoselective route to produce tris-o-substituted-(e)-( 3,5-dihydroxyphenyl)-2-(4- hydroxyphenyl)ethene
AU2003238899A1 (en) 2002-06-07 2003-12-22 Wisconsin Alumni Research Foundation Method of controling acetylation of metabolic enzymes
EP1549301A2 (en) 2002-06-10 2005-07-06 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
DE10230961A1 (en) 2002-07-10 2004-02-12 Lorenz, Peter, Dr. Use of hydroxyresveratrol or a mulberry extract to prepare a neuroprotective agent for preventing or treating diseases of the central and peripheral nervous systems
AU2003242965B2 (en) * 2002-07-11 2009-02-05 Dermipsor Ltd. Composition and methods for the treatment of skin disorders
WO2004009539A2 (en) 2002-07-19 2004-01-29 Orchid Chemicals And Pharmaceuticals Limited Method for the conversion of a z-isomer into e-isomer
DE10244282A1 (en) 2002-09-23 2004-04-01 Merck Patent Gmbh Preparation with antioxidant properties
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
US20040224039A1 (en) * 2003-02-12 2004-11-11 Donald Brucker Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
EP1633208A1 (en) 2003-05-27 2006-03-15 DSM IP Assets B.V. Novel nutraceutical compositions and use thereof
AU2004253579B2 (en) 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
US20050004052A1 (en) * 2003-07-03 2005-01-06 Technion Research & Development Foundation Ltd. Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes
US20050136429A1 (en) * 2003-07-03 2005-06-23 Massachusetts Institute Of Technology SIRT1 modulation of adipogenesis and adipose function
US20050038125A1 (en) * 2003-08-15 2005-02-17 Smit Hobbe Friso Method for the treatment of arthritis and pain
US20050049208A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and method of preventing diabetes
ES2530972T3 (en) 2003-09-12 2015-03-09 Elixir Pharmaceuticals Inc Methods of treatment of disorders
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
CA2548671C (en) 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
EP1604752B1 (en) * 2004-06-03 2008-03-19 Balcke-Dürr GmbH Method and device for hydraulic expansion
US7776326B2 (en) * 2004-06-04 2010-08-17 Washington University Methods and compositions for treating neuropathies
KR101331677B1 (en) 2004-09-24 2013-11-26 바이엘 크롭사이언스 엔.브이. Stress resistant plants
WO2006105440A2 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US8158856B2 (en) 2006-03-21 2012-04-17 Bayer Cropscience Nv Stress resistant plants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016726A2 (en) * 2002-08-09 2004-02-26 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSON R M ET AL: "MANIPULATION OF A NUCLEAR NAD+ SALVAGE PATHWAY DELAYS AGING WITHOUT ALTERING STEADY-STATE NAD+ LEVELS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 21, 24 May 2002 (2002-05-24), pages 18881 - 18890, XP007900540, ISSN: 0021-9258 *
BLANDER G ET AL: "THE SIR2 FAMILY OF PROTEIN DEACETYLASES", ANNUAL REVIEW OF BIOCHEMISTRY, PALTO ALTO, CA, US, vol. 73, 2004, pages 417 - 435, XP001206836, ISSN: 0066-4154 *

Also Published As

Publication number Publication date
JP2015180657A (en) 2015-10-15
US7977049B2 (en) 2011-07-12
AU2006212770A1 (en) 2006-08-17
CA2595495A1 (en) 2006-08-17
CA2595495C (en) 2014-12-09
US20120022013A1 (en) 2012-01-26
WO2006086454A2 (en) 2006-08-17
ES2401342T3 (en) 2013-04-18
JP2012176962A (en) 2012-09-13
US20050267023A1 (en) 2005-12-01
AU2006212770B2 (en) 2013-04-04
EP1851240A2 (en) 2007-11-07
EP1851240B1 (en) 2012-12-12
JP2008529502A (en) 2008-08-07

Similar Documents

Publication Publication Date Title
WO2006086454A3 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2004016726A3 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2006015209A3 (en) Differentiation of stem cells
WO2007008758A3 (en) Methods for identifying agents and conditions that modulate neurogenesis
WO2010033920A3 (en) Compositions and methods for enhancing cell reprogramming
WO2007059007A3 (en) Markers of definitive endoderm
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2006044480A3 (en) Nematode resistant transgenic plants
WO2007087153A3 (en) Cyst nematode resistant transgenic plants
TW200733453A (en) Method of using an electrochemical cell
WO2007118242A3 (en) Identification of a constitutively resistant cancer stem cell
WO2009126251A3 (en) Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator
WO2008066655A3 (en) Assessment of oocyte competence
WO2005113749A3 (en) Stem cell populations and methods of use
WO2006015887A3 (en) Modulation of alkaloid biosynthesis in plants and plants having altered alkaloid biosynthesis
WO2003022032A3 (en) Method for increasing stress tolerance in plants
WO2007143204A3 (en) Compositions and methods for modifying cell surface glycans
WO2006032707A3 (en) Plant cells and plants with increased tolerance to environmental stress
WO2008147536A8 (en) Methods and compositions for enhancing proteasome activity
WO2006055338A3 (en) Methods and systems for identifying and isolating stem cells and for observing mitochondrial structure and distribution in living cells
WO2006031591A3 (en) Methods and kits for isolating sperm cells
WO2002068635A3 (en) Methods of inhibiting expression of a target gene in mammalian cells
WO2005028621A3 (en) Assays with primary cells
WO2006107949A3 (en) Methods of protection from oxidative stress
WO2007075318A3 (en) Agents that reduce apoe-induced impairment of mitochondria and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2595495

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006212770

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007554337

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006212770

Country of ref document: AU

Date of ref document: 20060208

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006734562

Country of ref document: EP